Multivariate analysis for OS in treatment-naïve patients, WHO 2017 blast-based subgroups
| Variable . | P . | HR . | 95% CI for HR . | |
|---|---|---|---|---|
| WHO 2017 | ||||
| CMML-0 vs CMML-1 | .0212 | 0.732 | 0.561 | 0.954 |
| CMML-2 vs CMML-1 | .4136 | 1.118 | 0.856 | 1.459 |
| CMML-0 vs CMML-2 | .0019 | 0.655 | 0.501 | 0.855 |
| Hemoglobin concentration, g/dL | <.0001 | 0.862 | 0.819 | 0.908 |
| FAB subtype (MDS vs MP) | <.0001 | 0.513 | 0.410 | 0.640 |
| CPSS cytogenetic risk group | ||||
| High vs low | <.0001 | 2.470 | 1.826 | 3.342 |
| Intermediate vs low | .2721 | 1.202 | 0.866 | 1.669 |
| Age (<70 y vs ≥70 y) | .0093 | 0.745 | 0.596 | 0.930 |
| Variable . | P . | HR . | 95% CI for HR . | |
|---|---|---|---|---|
| WHO 2017 | ||||
| CMML-0 vs CMML-1 | .0212 | 0.732 | 0.561 | 0.954 |
| CMML-2 vs CMML-1 | .4136 | 1.118 | 0.856 | 1.459 |
| CMML-0 vs CMML-2 | .0019 | 0.655 | 0.501 | 0.855 |
| Hemoglobin concentration, g/dL | <.0001 | 0.862 | 0.819 | 0.908 |
| FAB subtype (MDS vs MP) | <.0001 | 0.513 | 0.410 | 0.640 |
| CPSS cytogenetic risk group | ||||
| High vs low | <.0001 | 2.470 | 1.826 | 3.342 |
| Intermediate vs low | .2721 | 1.202 | 0.866 | 1.669 |
| Age (<70 y vs ≥70 y) | .0093 | 0.745 | 0.596 | 0.930 |